Psychosis in a 12-Year-Old HIV-Positive Girl with an Increased Serum Concentration of Efavirenz
Open Access
- 15 November 2007
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (10), e128-e130
- https://doi.org/10.1086/522764
Abstract
Clearance and adverse effects of efavirenz are associated with CYP2B6-G516T polymorphism. Little is known about the prevalence of genotypes and implications for screening in children. We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T.Keywords
This publication has 9 references indexed in Scilit:
- Efavirenz Pharmacokinetics in HIV-1-Infected Children Are Associated With CYP2B6-G516T PolymorphismJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2005
- Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected SubjectsClinical Infectious Diseases, 2005
- Efavirenz Intoxication Due to Slow Hepatic MetabolismClinical Infectious Diseases, 2005
- Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patientsPharmacogenetics and Genomics, 2005
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- Psychiatric Hospitalizations Among Children and Youths With Human Immunodeficiency Virus InfectionPublished by American Academy of Pediatrics (AAP) ,2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityJournal of Pharmacology and Experimental Therapeutics, 2003
- Genetic contribution to variable human CYP3A-mediated metabolismAdvanced Drug Delivery Reviews, 2002